Part 4: Complication Prevention and Management

1. Central Line-Associated Bloodstream Infection (CLABSI)

1.1 Epidemiology in Oncology

CLABSI rates are disproportionately elevated in oncology populations compared to the general hospitalized population. Hematologic malignancy patients, stem cell transplant recipients, and patients with prolonged neutropenia face the highest risk. The oncology professional society and infection prevention expert panels identify the following risk factors as oncology-specific contributors:¹²³

Oncology-Specific Risk Factors for CLABSI:

Common Pathogens in Oncology CLABSI:

• Coagulase-negative staphylococci (most common overall)
• Staphylococcus aureus (including MRSA)
• Enterococci (including VRE)
• Gram-negative bacilli (Klebsiella, Pseudomonas, Escherichia coli, Enterobacter)
• Candida species (higher incidence in oncology than general population)
• Viridans group streptococci (particularly during mucositis)

1.2 CLABSI Prevention Bundle

The evidence-based CLABSI prevention bundle should be applied to all oncology CVADs. Elements include:²³

Insertion Bundle:

1. Hand hygiene before insertion
2. Maximal sterile barrier precautions (cap, mask, sterile gown, sterile gloves, full-body drape)
3. Chlorhexidine-alcohol skin antisepsis (2% CHG in 70% IPA)
4. Optimal site selection (avoid femoral site when possible)
5. Prompt removal of unnecessary CVADs

Maintenance Bundle:

1. Daily assessment of catheter necessity — remove when no longer required
2. Hand hygiene before and after catheter manipulation
3. Disinfect needleless connectors before each access (scrub the hub ≥5–15 seconds with 70% IPA)
4. Use passive disinfection caps on needleless connectors when feasible
5. Chlorhexidine-impregnated dressings at the insertion site
6. Standardized dressing changes at appropriate intervals (TSM every 7 days, gauze every 2 days)
7. Sterile technique for all dressing changes
8. Minimize catheter entry and manipulation frequency
9. Dedicate one lumen for TPN if parenteral nutrition is administered
10. Change administration sets per recommended intervals (standard fluids every 96 hours but at least every 7 days; lipid-containing solutions every 24 hours; blood products after each unit)

Bathing:

• Daily chlorhexidine bathing (2% CHG washcloths) for inpatients with CVADs has been shown to reduce CLABSI rates in intensive care and oncology populations²³
• Should not be applied directly to the CVAD insertion site (separate antiseptic protocol applies to the site)

1.3 Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)

When to Suspect CRBSI:

• Fever ≥38.0°C (100.4°F) without other identifiable source in a patient with a CVAD
• Rigors or hemodynamic instability temporally related to catheter use
• Erythema, tenderness, or purulence at the insertion site or port pocket
• New onset of sepsis in a patient with prolonged CVAD dwell time

Diagnostic Workup:

1. Obtain paired blood cultures: at least one set from the CVAD (each lumen if multi-lumen) and at least one set from a peripheral venipuncture site, drawn simultaneously or within close temporal proximity¹²
2. Differential time to positivity (DTP): If the CVAD blood culture becomes positive ≥2 hours before the peripheral culture, this strongly supports the catheter as the source of infection (sensitivity ~80%, specificity ~90%)
3. If purulent drainage is present at the insertion site or port pocket, obtain a culture of the drainage
4. Complete blood count, lactate, procalcitonin, and inflammatory markers as clinically indicated
5. Catheter tip culture (semi-quantitative roll plate method) should be obtained if the catheter is removed; growth of ≥15 colony-forming units of the same organism as the blood culture confirms catheter colonization²

1.4 CLABSI Management in Oncology

Decision Framework: Catheter Salvage vs. Removal

The decision to retain or remove a CVAD in the setting of confirmed or suspected CLABSI requires balancing infection control against the difficulty and risk of replacing the device in oncology patients with limited vascular access:¹⁴

Systemic Antibiotic Therapy:

• Initiate empiric broad-spectrum antibiotics immediately after blood cultures are drawn in febrile neutropenic patients with CVADs, per institutional febrile neutropenia protocols
• Narrow antibiotic therapy based on culture results and sensitivities
• Duration: typically 10–14 days from the first negative blood culture (for uncomplicated CRBSI with catheter removal) or 14 days of systemic antibiotics plus antimicrobial lock therapy (for catheter salvage)
• S. aureus bacteremia requires a minimum of 4–6 weeks of systemic antibiotic therapy regardless of catheter removal, with echocardiography to rule out endocarditis⁴
• Candidemia requires at least 14 days of antifungal therapy after the first negative blood culture, with ophthalmologic evaluation for endophthalmitis

Antimicrobial Lock Therapy for Catheter Salvage:

When catheter salvage is attempted, antimicrobial lock therapy is used as an adjunct to systemic antibiotics:¹⁴

• Instill concentrated antibiotic solution into the catheter lumen(s)
• Dwell time: minimum 8–12 hours per day (typically overnight when catheter is not in active use)
• Duration: 10–14 days
• Common lock solutions: vancomycin (2–5 mg/mL), gentamicin (1–2 mg/mL), daptomycin (5 mg/mL), ethanol 70%
• The lock solution should contain the antibiotic to which the isolated organism is susceptible

2. Catheter-Associated Thrombosis (CAT)

2.1 Incidence and Risk in Oncology

Catheter-associated thrombosis is a significant complication in oncology patients, with reported symptomatic rates of 2–15% for ports and 5–30% for PICCs in cancer populations, depending on the diagnostic methodology and surveillance intensity used. Asymptomatic thrombosis detected by screening ultrasound is considerably more common.⁵⁶⁷

2.2 Clinical Presentation

Many catheter-associated thromboses are asymptomatic and discovered incidentally on imaging. When symptoms occur, they may include:⁵⁶

• Pain in the affected extremity, shoulder, neck, or chest
• Unilateral limb edema
• Erythema of the extremity
• Visible distension of peripheral veins in the affected limb
• New onset of visible venous collaterals on the chest wall
• Difficulty flushing or aspirating from the catheter (suggests intraluminal thrombus or fibrin sheath)
• Sense of “tightness” or “pulling” reported by the patient

Important: An increase in mid-arm circumference of ≥3 cm compared to the baseline measurement recorded at PICC insertion is associated with catheter-related DVT and should prompt diagnostic evaluation.⁵

2.3 Diagnosis

• Color-flow Doppler ultrasonography is the initial diagnostic study. Catheter-associated DVT is confirmed when at least two of the following are present: echogenic mass within the vein, noncompressibility of the vein, abnormal color Doppler flow pattern, or venous filling defect.⁵
• For evaluation of proximal veins that may be obscured by the clavicle (brachiocephalic vein, SVC), contrast venography or CT venography may be necessary.
• Incidental thrombosis discovered on CT scans performed for cancer staging or surveillance should be managed in the same manner as symptomatic thrombosis.

2.4 Prevention

Device Selection:

• Implanted ports are associated with lower thrombotic risk than PICCs in oncology populations and should be preferred for long-term access⁶⁷⁸
• Select the smallest diameter catheter with fewest lumens necessary
• Maintain catheter-to-vessel ratio ≤45% for PICCs (measured by ultrasound before insertion)⁵

Insertion Technique:

• Ultrasound-guided insertion with minimal vessel trauma
• Optimal catheter tip positioning at the CAJ (malposition increases thrombosis risk)⁵⁶
• IC-ECG-guided PICC placement has been associated with reduced thrombotic complications⁹

Post-Insertion:

• Upper extremity exercise (handgrip exercise using an elastic ball, 3–6 times daily for 3 weeks following PICC insertion) has been associated with decreased DVT incidence in cancer patients⁵¹⁰
• Adequate hydration during chemotherapy
• Baseline arm circumference measurement and documentation at time of PICC or midline insertion for serial monitoring

Pharmacologic Prophylaxis:

• Universal prophylactic anticoagulation for all cancer patients with CVADs has not been established as standard practice, though VTE prophylaxis is recommended for cancer patients during active treatment with central venous access⁶¹¹
• For high-risk oncology patients (e.g., pancreatic cancer, myeloma on lenalidomide plus dexamethasone), thromboprophylaxis with LMWH or DOAC should follow cancer-specific VTE prevention guidelines
• Individualized risk-benefit assessment considering bleeding risk from thrombocytopenia

2.5 Management of Confirmed CAT

Catheter Retention:

The catheter may be retained if it remains correctly positioned, functional, and necessary for ongoing therapy. Catheter removal for documented CAT is recommended when:⁶¹¹

• The catheter is no longer needed
• The catheter is malfunctioning
• Symptoms are severe and not improving with anticoagulation
• Catheter-associated septic thrombophlebitis is present

Anticoagulation Therapy:

• Low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) are the agents of choice for treatment of catheter-associated DVT in cancer patients⁶¹¹
• Duration: minimum 3 months from diagnosis; if the CVAD is retained, anticoagulation should continue for the duration of catheter dwell time
• In patients with severe symptoms, initial treatment with unfractionated heparin infusion may be warranted before transitioning to LMWH or DOAC
• Catheter-directed thrombolysis may be considered for severe, limb-threatening thrombosis or SVC syndrome, but requires careful assessment of bleeding risk, particularly in thrombocytopenic patients

Post-Thrombotic Syndrome:

Clinicians should be aware that post-thrombotic syndrome may develop as a long-term sequela of catheter-associated DVT, manifesting as persistent pain, edema, and skin changes in the affected extremity.⁵

3. Catheter Occlusion

3.1 Classification and Assessment

A systematic approach to occlusion assessment is essential for appropriate management:¹²¹³

Occlusion Types:

Assessment Steps:

1. Assess external factors first: check clamps, tubing kinks, connector obstruction, securement device constriction
2. For ports: verify noncoring needle is fully seated
3. Attempt patient repositioning (raise arm, cough, deep breathing, change body position)
4. Attempt gentle aspiration directly at the catheter hub (remove extension set)
5. Review recent infusion history to identify potential chemical precipitants
6. Assess for clinical signs of thrombosis (limb edema, pain)

3.2 Treatment of Thrombotic Occlusion

Tissue Plasminogen Activator (tPA, Alteplase):

Alteplase is the primary thrombolytic agent for CVAD occlusion restoration:¹²¹³

Administration Procedure:

1. Assess for contraindications to thrombolytic therapy (active internal bleeding, known intracranial neoplasm with high bleeding risk — weigh risk-benefit)
2. Stop all infusions
3. Instill alteplase into the occluded lumen(s) — treat ALL occluded lumens, not only the one needed for immediate use
4. Allow to dwell for the prescribed time
5. Attempt aspiration at 30-minute intervals
6. If unsuccessful after initial dwell, one additional instillation may be performed
7. Once patency is restored, aspirate and discard the alteplase-blood mixture, then flush with 10 mL of 0.9% sodium chloride

Alternative Thrombolytic Agents:

Urokinase, reteplase, and tenecteplase have been studied in smaller trials and may be considered when alteplase is unavailable or contraindicated. Additional comparative research is needed to establish relative efficacy.¹²

Alternative Administration Methods for Persistent Occlusion:

• Push method: slow administration over 30 minutes
• Low-dose infusion over 30 minutes to 3–4 hours
• These approaches may be considered for persistent or recurring occlusions not resolved by standard instillation¹²

3.3 Treatment of Chemical Occlusion

When chemical occlusion is suspected based on the types of medications administered, appropriate catheter-clearance agents should be selected based on the presumed precipitant:¹²¹³

Procedure:

1. Instill the appropriate catheter-clearance agent into the affected lumen based on catheter priming volume
2. Allow to dwell for 20–60 minutes
3. Aspirate degradation products and discard
4. Flush with 10 mL of 0.9% sodium chloride to assess restored patency
5. If unsuccessful, one additional attempt may be made

3.4 Unresolved Occlusion

When occlusion cannot be resolved with standard interventions:¹²

1. Obtain radiographic imaging to evaluate catheter tip position and rule out malposition
2. Refer to interventional radiology for contrast study evaluation or procedural interventions (snare removal of fibrin, fibrin sheath disruption, catheter exchange)
3. Investigate for underlying catheter-associated thrombosis (venous Doppler ultrasound)
4. If all restoration efforts fail, plan for catheter removal and alternative vascular access

4. Extravasation

4.1 Oncology-Specific Extravasation Risks

Extravasation of vesicant chemotherapy through a CVAD represents a serious complication with potential for severe tissue injury. In the port setting, extravasation occurs primarily through:¹⁴¹⁵

• Needle dislodgement: The noncoring needle displaces from the port septum during infusion
• Catheter disconnection from port body: Rare but catastrophic
• Catheter fracture or rupture: May result from pinch-off syndrome, catheter fatigue, or excessive injection pressure
• Catheter erosion through the vessel wall: Secondary to malposition or vessel wall contact over time
• Fibrin sheath formation: Causes backflow of infusate along the external catheter surface and into surrounding tissue

For PICCs and tunneled catheters, extravasation may occur from catheter tip migration, catheter damage, or partial dislodgement.

4.2 Prevention

Confirming patency before vesicant administration is mandatory:

1. Verify blood return from the catheter before initiating vesicant chemotherapy
2. Flush with 10 mL of 0.9% sodium chloride and assess for ease of flow, absence of resistance, and absence of swelling or pain at the site
3. For ports: confirm noncoring needle is fully seated; ensure secure needle stabilization
4. Monitor the patient continuously during vesicant chemotherapy infusion; assess the site and ask about pain, burning, or stinging at frequent intervals (every 5–10 minutes for peripheral vesicant infusions; at each nurse assessment for central infusions)¹⁴
5. Educate patients to immediately report any pain, burning, stinging, or swelling at or near the CVAD site during infusion

Critical Safety Point: If blood return is absent and cannot be established through troubleshooting, vesicant chemotherapy should not be initiated until catheter function is confirmed through alternative means (e.g., radiographic dye study confirming intravascular tip position and flow). This applies to all CVAD types including implanted ports.¹⁴¹⁵

4.3 Management of CVAD-Related Extravasation

Immediate Actions:

1. Stop the infusion immediately — do not remove the needle or catheter yet
2. Aspirate as much of the extravasated agent as possible through the CVAD
3. Estimate the volume of extravasated agent
4. Notify the prescribing physician and oncology team
5. Administer the appropriate antidote if one exists for the specific agent (see table below)
6. Remove the noncoring needle (ports) or withdraw the catheter (after aspiration attempt)
7. Do NOT apply pressure to the extravasation site (may spread the vesicant agent)
8. Apply thermal therapy as indicated by the specific agent
9. Elevate the affected extremity
10. Document the event, estimated volume extravasated, site appearance, interventions, and patient response
11. Arrange follow-up assessment within 24–48 hours and serially thereafter
12. Obtain surgical consultation if tissue necrosis develops or large-volume vesicant extravasation has occurred

Antidote Protocols for Common Oncology Vesicants:

Dexrazoxane Protocol for Anthracycline Extravasation:

• Administer IV within 6 hours of extravasation
• Day 1: 1,000 mg/m² (max 2,000 mg)
• Day 2: 1,000 mg/m² (max 2,000 mg)
• Day 3: 500 mg/m² (max 1,000 mg)
• Infuse over 1–2 hours in a large vein in an extremity other than the affected area
• Do not use concurrently with topical DMSO (choose one or the other)¹⁴¹⁵

5. Catheter Malposition

5.1 Primary Malposition

Primary malposition occurs during or immediately after insertion when the catheter tip is placed in an unintended location. Risk factors in oncology include:¹⁶

• Left-sided insertions (longer, more angled course to SVC)
• Mediastinal tumor distorting venous anatomy
• Prior venous thrombosis or stenosis
• Congenital venous anomalies (persistent left SVC)
• Venous compression from lymphadenopathy

Prevention:

• Real-time ultrasound and fluoroscopic guidance during insertion
• IC-ECG confirmation for PICC placement
• Post-procedure chest radiograph confirmation for all CVADs
• Awareness of patient anatomy from pre-procedure imaging review

5.2 Secondary Malposition (Tip Migration)

Tip migration during dwell time may occur due to:¹⁶

• Changes in intrathoracic pressure (coughing, vomiting, straining)
• Positive pressure ventilation
• Arm or neck movement
• Catheter dislodgement (partial withdrawal)
• Development of venous thrombosis
• Growth in pediatric patients

Clinical Indicators:

• New difficulty flushing or absent blood return
• Change in external catheter length (PICCs, tunneled catheters)
• New arrhythmias
• Pain during infusion
• Swelling near the insertion site or along the catheter tract
• Patient hearing gurgling sounds on the ipsilateral side

Critical Safety Point: Infusion should be withheld through a malpositioned catheter until appropriate tip position is confirmed. If continued therapy is required, assess whether the prescribed regimen is peripherally compatible and insert a short peripheral catheter as a bridge.¹⁶

5.3 Management

• Noninvasive repositioning: Elevate the head of bed to 60–90 degrees; perform a forceful flush through the catheter while the patient coughs (may redirect a catheter that has migrated into the jugular vein)
• Intracardiac malposition: If the tip has migrated deep into the right atrium or ventricle, retract the catheter to the appropriate position using IC-ECG or chest radiograph guidance
• Invasive repositioning: If noninvasive methods fail, interventional radiology can perform fluoroscopic repositioning using snare techniques
• Never advance an external portion of a CVAD that has contacted skin back into the insertion site — no antiseptic can render skin sterile. Management requires catheter exchange over a guidewire or new insertion at a different site.¹⁶

6. Pinch-Off Syndrome

6.1 Definition and Mechanism

Pinch-off syndrome occurs when a catheter inserted via the subclavian vein becomes compressed between the clavicle and the first rib in the costoclavicular space. Repetitive compression can lead to catheter fatigue, intermittent or complete obstruction, and ultimately catheter fracture with potential embolization of the distal fragment.¹²¹⁶

6.2 Clinical Indicators

• Intermittent difficulty flushing or aspirating that correlates with arm position or shoulder movement
• Patient reports of arm or shoulder discomfort
• Catheter function that improves when the patient raises the ipsilateral arm or rolls the shoulder backward
• New arrhythmias (may indicate catheter fragment embolization)
• Change in external catheter length (suggests fracture)

6.3 Diagnostic Evaluation

• Chest radiograph with the arm adducted and abducted to demonstrate catheter compression
• Fluoroscopy may show intermittent catheter narrowing during arm movement
• CT imaging may identify catheter impingement in the costoclavicular space

6.4 Management

• If pinch-off is confirmed and the catheter is intact but compressed, device removal is recommended before fracture occurs
• If catheter fracture has occurred, the embolized fragment must be retrieved, typically by interventional radiology using intravascular snare techniques
• Replacement device should be placed using a different approach (internal jugular vein or contralateral subclavian with a lateral puncture technique to avoid the costoclavicular space)

7. Catheter Damage and Repair

7.1 Types of Catheter Damage

• External catheter cracking or breakage: Most common with tunneled silicone catheters from repeated clamping
• Hub separation: Disconnection at the junction of the catheter and hub
• Catheter leak: Visible fluid leak from a damaged segment
• Internal catheter fracture: May result from pinch-off syndrome; catheter fragment may embolize

7.2 Immediate Management

If external catheter damage is identified:¹²

1. Clamp the catheter between the damaged area and the patient (proximal to the damage) to prevent air embolism and blood loss
2. Apply a sterile dressing over the damaged site
3. Do not use the catheter for infusion until repair or replacement is accomplished
4. Assess whether repair or replacement is more appropriate:
   • Repair kits are available from manufacturers for some tunneled silicone catheters
   • PICCs and polyurethane catheters generally cannot be repaired and require replacement
   • Port catheter damage requires surgical intervention (replacement)

7.3 Air Embolism Prevention

Catheter disconnection or damage creates a risk of venous air embolism. If air embolism is suspected (sudden dyspnea, chest pain, hypotension, altered mental status):²

1. Clamp the catheter immediately
2. Place the patient in left lateral decubitus position with head down (Durant maneuver)
3. Administer 100% oxygen
4. Call for emergency assistance
5. Aspiration of air through the CVAD or right heart catheterization may be attempted in severe cases

References